These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 6101413)

  • 1. Artificial surfactant therapy in hyaline-membrane disease.
    Fujiwara T; Maeta H; Chida S; Morita T; Watabe Y; Abe T
    Lancet; 1980 Jan; 1(8159):55-9. PubMed ID: 6101413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactant treatment in the neonate with severe respiratory distress syndrome.
    Horpaopan S; Sangtaveesin V; Ratrisawasdi V
    J Med Assoc Thai; 1996 Apr; 79(4):222-8. PubMed ID: 8708507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactant replacement in spontaneously breathing babies with hyaline membrane disease--a pilot study.
    Victorin LH; Deverajan LV; Curstedt T; Robertson B
    Biol Neonate; 1990; 58(3):121-6. PubMed ID: 2279046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The therapeutic use of pulmonary surfactant in neonatal hyaline membrane disease].
    Lozano-González CH; Piña-Ceballos VM; Beyer-Obezo J; Gutiérrez-Martín A; Martínez-Hinojosa B; Flores-Támez ME
    Bol Med Hosp Infant Mex; 1993 Jul; 50(7):481-91. PubMed ID: 8363747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants.
    Namgung R; Lee C; Suh JS; Park KI; Han DG
    Yonsei Med J; 1989 Dec; 30(4):355-66. PubMed ID: 2697112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventilation-perfusion relationships in preterm infants after surfactant treatment.
    Bowen W; Martin CR; Krauss AN; Auld PA
    Pediatr Pulmonol; 1994 Sep; 18(3):155-62. PubMed ID: 7800432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease.
    Couser RJ; Ferrara TB; Ebert J; Hoekstra RE; Fangman JJ
    J Pediatr; 1990 Jan; 116(1):119-24. PubMed ID: 2404097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaline-membrane disease: therapy with constant lung-distending pressure.
    Chernick V
    N Engl J Med; 1973 Aug; 289(6):302-4. PubMed ID: 4577904
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyaline membrane disease treated with bovine surfactant.
    Smyth JA; Metcalfe IL; Duffty P; Possmayer F; Bryan MH; Enhorning G
    Pediatrics; 1983 Jun; 71(6):913-7. PubMed ID: 6687937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease.
    Raju TN; Vidyasagar D; Bhat R; Sobel D; McCulloch KM; Anderson M; Maeta H; Levy PS; Furner S
    Lancet; 1987 Mar; 1(8534):651-6. PubMed ID: 2882083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study].
    Sánchez-Mendiola M; Martínez-Natera OC; Herrera-Maldonado N; Ortega-Arroyo J
    Gac Med Mex; 2005; 141(4):267-71. PubMed ID: 16164120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The late administration of surfactant.
    Ballot DE; Rothberg AD; Davies VA
    S Afr Med J; 1995 Jul; 85(7):644-6. PubMed ID: 7482080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The circulation, fluid transfers and surface activity in the lungs of infants with hyaline membrane disease.
    Normand IC
    Bull Physiopathol Respir (Nancy); 1973; 9(6):1473-94. PubMed ID: 4602246
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of single dose surfactant on pulmonary function.
    Bhat R; Dziedzic K; Bhutani VK; Vidyasagar D
    Crit Care Med; 1990 Jun; 18(6):590-5. PubMed ID: 2111754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease.
    Gitlin JD; Soll RF; Parad RB; Horbar JD; Feldman HA; Lucey JF; Taeusch HW
    Pediatrics; 1987 Jan; 79(1):31-7. PubMed ID: 3540835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous surfactant therapy in hyaline membrane disease.
    Gitlin JD; Parad R; Taeusch HW
    Semin Perinatol; 1984 Oct; 8(4):272-82. PubMed ID: 6387924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resuscitation and respiratory management of infants weighing less than 1000 grams.
    Bhat R; Zikos-Labropoulou E
    Clin Perinatol; 1986 Jun; 13(2):285-97. PubMed ID: 3755084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study Group.
    Soll RF; Hoekstra RE; Fangman JJ; Corbet AJ; Adams JM; James LS; Schulze K; Oh W; Roberts JD; Dorst JP
    Pediatrics; 1990 Jun; 85(6):1092-102. PubMed ID: 2187176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of HMD, ICU's, CPAP and Jenner.
    Nelson NM
    N Engl J Med; 1971 Jun; 284(24):1376-8. PubMed ID: 4930605
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary function in infants with neonatal chronic lung disease with or without hyaline membrane disease at birth.
    Merth IT; de Winter JP; Zonderland HM; Borsboom GJ; Quanjer PH
    Eur Respir J; 1997 Jul; 10(7):1606-13. PubMed ID: 9230255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.